Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study

{ 'indexed': {'date-parts': [[2024, 2, 13]], 'date-time': '2024-02-13T17:26:03Z', 'timestamp': 1707845163613}, 'reference-count': 13, 'publisher': 'Oxford University Press (OUP)', 'issue': '3', 'license': [ { 'start': { 'date-parts': [[2023, 9, 6]], 'date-time': '2023-09-06T00:00:00Z', 'timestamp': 1693958400000}, 'content-version': 'vor', 'delay-in-days': 67, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2023, 7, 1]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>Tixagevimab and cilgavimab (Evusheld) are 2 fully human monoclonal ' 'antibodies that received emergency-use authorization on December 21, 2021, for pre-exposure ' 'prophylaxis of coronavirus disease 2019 (COVID-19) in patients who are moderate–severely ' 'immunocompromised. The real-world efficacy of Evusheld in patients with inflammatory bowel ' 'disease (IBD) is not known.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>We conducted a retrospective cohort study using TriNetX, a ' 'multi-institutional database in patients with IBD who received Evusheld compared to patients ' 'with IBD who did not receive Evusheld (12.1.2021–10.28.2022). The primary outcome was to ' 'assess the risk of COVID-19 within 6 months. One-to-one propensity score matching (PSM) was ' 'performed for demographic parameters, comorbid conditions, IBD medications, and history of ' 'COVID-19. Risk was expressed as adjusted odds ratio (aOR) with 95% confidence interval ' '(CI).</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>Four hundred and eight patients (0.19%) with IBD received Evusheld ' '(mean age 58.6 ± 15.4 years old, female 47.7%) during the study period. After PSM, there was ' 'no difference in the risk (aOR 0.88, 95% CI, 0.33–2.35) of COVID-19 in the Evusheld cohort ' 'compared to the IBD control cohort. No patients required ICU care or intubation/respiratory ' 'support or were deceased in the Evusheld cohort.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusions</jats:title>\n' ' <jats:p>Our study did not show that Evusheld decreases the risk of COVID-19 ' 'in patients with IBD. Prevention of moderate–severe COVID-19 in these patients should focus ' 'on vaccination strategies and early COVID-19 therapies.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1093/crocol/otad047', 'type': 'journal-article', 'created': {'date-parts': [[2023, 9, 6]], 'date-time': '2023-09-06T16:30:20Z', 'timestamp': 1694017820000}, 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With ' 'Inflammatory Bowel Disease: A Propensity Matched Cohort Study', 'prefix': '10.1093', 'volume': '5', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-6604-7712', 'authenticated-orcid': False, 'given': 'Aakash', 'family': 'Desai', 'sequence': 'first', 'affiliation': [ { 'name': 'Division of Gastroenterology and Hepatology, MetroHealth Medical ' 'Center, Case Western Reserve University , Cleveland, OH , USA'}]}, { 'ORCID': 'http://orcid.org/0000-0001-8305-9742', 'authenticated-orcid': False, 'given': 'Jana G', 'family': 'Hashash', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Gastroenterology and Hepatology, Mayo Clinic , ' 'Jacksonville, FL , USA'}]}, { 'given': 'Gursimran S', 'family': 'Kochhar', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Gastroenterology & Hepatology, Allegheny Health ' 'Network , Pittsburgh, PA , USA'}]}, { 'given': 'Francis A', 'family': 'Farraye', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Gastroenterology and Hepatology, Mayo Clinic , ' 'Jacksonville, FL , USA'}]}], 'member': '286', 'published-online': {'date-parts': [[2023, 9, 6]]}, 'reference': [ { 'issue': '635', 'key': '2023090616205803500_CIT0001', 'doi-asserted-by': 'crossref', 'first-page': 'eabl8124', 'DOI': '10.1126/scitranslmed.abl8124', 'article-title': 'The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective ' 'in nonhuman primates and has an extended half-life in humans', 'volume': '14', 'author': 'Loo', 'year': '2022', 'journal-title': 'Sci Transl Med.'}, { 'issue': '23', 'key': '2023090616205803500_CIT0002', 'doi-asserted-by': 'crossref', 'first-page': '2188', 'DOI': '10.1056/NEJMoa2116620', 'article-title': 'Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of ' 'COVID-19', 'volume': '386', 'author': 'Levin', 'year': '2022', 'journal-title': 'N Engl J Med.'}, {'key': '2023090616205803500_CIT0003'}, { 'issue': '12', 'key': '2023090616205803500_CIT0004', 'doi-asserted-by': 'crossref', 'first-page': '1654.e1', 'DOI': '10.1016/j.cmi.2022.07.015', 'article-title': 'Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) ' 'for COVID-19 among 1112 severely immunocompromised patients', 'volume': '28', 'author': 'Nguyen', 'year': '2022', 'journal-title': 'Clin Microbiol Infect'}, { 'issue': '1', 'key': '2023090616205803500_CIT0005', 'doi-asserted-by': 'crossref', 'first-page': '96', 'DOI': '10.1016/j.amjmed.2022.08.019', 'article-title': 'The prevention of COVID-19 in high-risk patients using ' 'tixagevimab–cilgavimab (Evusheld): Real-world experience at a large ' 'academic center', 'volume': '136', 'author': 'Al-Obaidi', 'year': '2022', 'journal-title': 'Am J Med.'}, { 'issue': '5', 'key': '2023090616205803500_CIT0006', 'doi-asserted-by': 'crossref', 'first-page': '705', 'DOI': '10.1093/ibd/izac131', 'article-title': 'A systematic review of Crohn’s disease case definitions in ' 'administrative or claims databases', 'volume': '29', 'author': 'Hutfless', 'year': '022', 'journal-title': 'Inflamm Bowel Dis.'}, { 'key': '2023090616205803500_CIT0007', 'doi-asserted-by': 'crossref', 'first-page': 'izac252', 'DOI': '10.1093/ibd/izac252', 'article-title': 'Effect of 2 vs 3 doses of COVID-19 vaccine in patients with ' 'inflammatory bowel disease: a population-based propensity matched ' 'analysis', 'author': 'Desai', 'year': '2022', 'journal-title': 'Inflamm Bowel Dis.'}, { 'issue': '9', 'key': '2023090616205803500_CIT0008', 'doi-asserted-by': 'crossref', 'first-page': '1999', 'DOI': '10.3390/v14091999', 'article-title': 'A critical analysis of the use of cilgavimab plus tixagevimab ' 'monoclonal antibody cocktail (EvusheldTM) for COVID-19 prophylaxis and ' 'treatment', 'volume': '14', 'author': 'Focosi', 'year': '2022', 'journal-title': 'Viruses'}, { 'issue': '2', 'key': '2023090616205803500_CIT0009', 'doi-asserted-by': 'crossref', 'first-page': '109', 'DOI': '10.1097/RHU.0000000000001907', 'article-title': 'Real-world experience of tixagevimab and cilgavimab (Evusheld) in ' 'rheumatologic patients on rituximab', 'volume': '29', 'author': 'Ocon', 'year': '2022', 'journal-title': 'J Clin Rheumatol'}, { 'issue': '11', 'key': '2023090616205803500_CIT0010', 'doi-asserted-by': 'crossref', 'first-page': '2537', 'DOI': '10.1016/j.ekir.2022.08.019', 'article-title': 'Tixagevimab and cilgavimab (Evusheld) in rituximab-treated ' 'antineutrophil cytoplasmic antibody vasculitis patients', 'volume': '7', 'author': 'Aqeel', 'year': '2022', 'journal-title': 'Kidney Int Rep'}, { 'issue': '12', 'key': '2023090616205803500_CIT0011', 'doi-asserted-by': 'crossref', 'first-page': '3130', 'DOI': '10.1111/ajt.17128', 'article-title': 'Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with ' 'lower breakthrough infection risk in vaccinated solid organ transplant ' 'recipients during the omicron wave', 'volume': '22', 'author': 'Al Jurdi', 'year': '2022', 'journal-title': 'Am J Transplant.'}, { 'issue': '3', 'key': '2023090616205803500_CIT0012', 'article-title': 'Efficacy of Paxlovid and Lagevrio for COVID-19 infection in patients ' 'with inflammatory bowel disease: a propensity-matched study', 'volume': '21', 'author': 'Hashah', 'year': '2022', 'journal-title': 'Clin Gastroenterol Hepatol.'}, { 'key': '2023090616205803500_CIT0013', 'author': 'FDA announces Evusheld is not currently authorized for emergency use in the ' 'U.S', 'year': '2023'}], 'container-title': "Crohn's &amp; Colitis 360", 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://academic.oup.com/crohnscolitis360/article-pdf/5/3/otad047/51393532/otad047.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/crohnscolitis360/article-pdf/5/3/otad047/51393532/otad047.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 9, 6]], 'date-time': '2023-09-06T16:30:27Z', 'timestamp': 1694017827000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://academic.oup.com/crohnscolitis360/article/doi/10.1093/crocol/otad047/7261634'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 7, 1]]}, 'references-count': 13, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2023, 7, 1]]}}, 'URL': 'http://dx.doi.org/10.1093/crocol/otad047', 'relation': {}, 'ISSN': ['2631-827X'], 'subject': ['Gastroenterology'], 'published-other': {'date-parts': [[2023, 7, 1]]}, 'published': {'date-parts': [[2023, 7, 1]]}}